PT  - JOURNAL ARTICLE
AU  - Perlis, Roy H.
AU  - Santillana, Mauricio
AU  - Ognyanova, Katherine
AU  - Lazer, David
TI  - Correlates of symptomatic remission among individuals with post-COVID-19 condition
AID  - 10.1101/2023.01.31.23285246
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.01.31.23285246
4099  - http://medrxiv.org/content/early/2023/02/01/2023.01.31.23285246.short
4100  - http://medrxiv.org/content/early/2023/02/01/2023.01.31.23285246.full
AB  - Importance Post-COVID-19 condition (PCC), or long COVID, has become prevalent. The course of this syndrome, and likelihood of remission, has not been characterized.Objective To quantify the rates of remission of PCC, and the sociodemographic features associated with remission.Design 16 waves of a 50-state U.S. non-probability internet survey conducted between August 2020 and November 2022Setting Population-basedParticipants Survey respondents age 18 and olderMain Outcome and Measure PCC remission, defined as reporting full recovery from COVID-19 symptoms among individuals who on a prior survey wave reported experiencing continued COVID-19 symptoms beyond 2 months after the initial month of symptoms.Results Among 423 survey respondents reporting continued symptoms more than 2 months after acute test-confirmed COVID-19 illness, who then completed at least 1 subsequent survey, mean age was 53.7 (SD 13.6) years; 293 (69%) identified as women, and 130 (31%) as men; 9 (2%) identified as Asian, 29 (7%) as Black, 13 (3%) as Hispanic, 15 (4%) as another category including Native American or Pacific Islander, and the remaining 357 (84%) as White. Overall, 131/423 (31%) of those who completed a subsequent survey reported no longer being symptomatic. In Cox regression models, male gender, younger age, lesser impact of PCC symptoms at initial visit, and infection when the Omicron strain predominated were all statistically significantly associated with greater likelihood of remission; presence of ‘brain fog’ or shortness of breath were associated with lesser likelihood of remission.Conclusions and Relevance A minority of individuals reported remission of PCC symptoms, highlighting the importance of efforts to identify treatments for this syndrome or means of preventing it.Trial registration N/AQuestion How often do individuals with post-COVID-19 condition, or long COVID, recover fully, and what predicts this recovery?Findings Among 423 individuals who initially reported post-COVID-19 condition and completed at least one subsequent survey, 131 (31%) later described symptomatic remission. Younger age, male gender, lesser symptom severity at initial survey, and infection during Omicron-predominance were associated with greater likelihood of reporting recovery.Meaning A minority of people with post-COVID-19 condition report spontaneous remission of symptoms, highlighting the importance of developing treatments for this syndrome.Competing Interest StatementDr. Perlis has received personal fees from Burrage Capital, Genomind, Circular Genomics, Psy Therapeutics, and Takeda outside the current work. He is an Associate Editor at JAMA Network Open. The other authors report no competing interests.Funding StatementThe survey was supported in part by the National Science Foundation (Drs. Ognyanova and Lazer) and by the National Institute of Mental Health (Drs. Perlis and Lazer - RF1MH132335).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been classified as exempt by the Institutional Review Board of Harvard UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not yet available for distribution